

Highly Potent and Selective Histone Deacetylase 6 Inhibitors Designed Based on a Small-Molecular Substrate

Takayoshi Suzuki,^{*,†} Akiyasu Kouketsu,[†] Yukihiro Itoh,[†] Shinya Hisakawa,[†] Satoko Maeda,[‡] Minoru Yoshida,^{‡,§} Hidehiko Nakagawa,[†] and Naoki Miyata^{*,†}

Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan, RIKEN, Saitama 351-0198, Japan, and CREST Research Project, Japan Science and Technology Agency, Saitama 332-001, Japan

Received May 11, 2006

Abstract: To find novel histone deacetylase 6 (HDAC6)-selective inhibitors and clarify the structural requirements for HDAC6-selective inhibition, we prepared thiolate analogues designed based on the structure of an HDAC6-selective substrate and evaluated the histone/ α -tubulin acetylation selectivity by Western blot analysis. Aliphatic compounds **17b–20b** selectively caused α -tubulin acetylation over histone H4 acetylation. In enzyme assays using HDAC1, HDAC4, and HDAC6, compounds **17a–19a** exhibited HDAC6-selective inhibition over HDAC1 and HDAC4.

Introduction

Histone deacetylases^a (HDACs) are responsible for the deacetylation of the acetylated lysine residues in the N-terminal region of the core histones and are involved in transcriptional regulation, cell cycle progression, and developmental events.¹ Thus far, eighteen HDAC family members have been identified, and they are divided into two categories, i.e., zinc-dependent enzymes (HDAC1–11) and NAD⁺-dependent enzymes (SIRT1–7).^{1a,2} HDAC6, a zinc-dependent HDAC isoform, is unique in that it is cytoplasmic and participates in the deacetylation of nonhistone proteins, such as α -tubulin and HSP90, as well as regulating important biological processes including microtubule stability and function, and molecular chaperon activity.³ In addition, it has recently been reported that inhibition of HDAC6 has an antitumor effect in multiple myeloma cells.⁴ Thus, HDAC6-selective inhibitors are of interest not only as tools for elucidating the more intricate biological functions of HDAC6, but also as candidate antitumor agents.

A number of structurally diverse HDAC inhibitors have been identified,⁵ including **1** (trichostatin A, TSA),⁶ **2** (suberoylanilide hydroxamic acid, SAHA),⁷ **3** (CHAP31),⁸ **4** (trapoxin B, TPX B),^{6b,9} and **5** (MS-275)¹⁰ (Chart 1). Most hydroxamates, such as **1** and **2**, inhibit all of the HDAC isoforms, whereas most non-hydroxamates, such as **4** and **5**, do not inhibit HDAC6.^{3b,c,11} To date, the only known HDAC6-selective inhibitor is **6** (tubacin) (Chart 1), which was discovered using a combinatorial approach.¹² At present, there is little information about the structural requirements for HDAC6-selective inhibition. There-

Chart 1. Examples of HDAC Inhibitors





Chart 2. Thiolate HDAC Inhibitors



fore, there is a need to develop novel HDAC6-selective inhibitors and then to study their structure–activity relationships.

We recently described a series of thiol-based analogues, including **7** (NCH-26) and **8** (NCH-31) (Chart 2), which act as novel non-hydroxamate HDAC inhibitors.¹³ Thiols are thought to inhibit HDACs by coordinating the zinc ion which is required for deacetylation of the acetylated lysine substrate. Further, the *S*-isobutyryl prodrugs **9** (NCH-47) and **10** (NCH-51) (Chart 2), which are thought to be hydrolyzed to the free thiols within cells, showed potent cancer cell growth-inhibitory activities.¹⁴ Following these findings, we performed further investigation of thiolate analogues, seeking to find HDAC6-selective inhibitors. We describe here the HDAC6 selectivity of thiolates whose designs were based on the structure of a small-molecular HDAC6-selective substrate.

Results and Discussion

Since HDAC6 has been reported as an α -tubulin deacetylase,^{3b,3c} inhibition of HDAC6 and that of other HDACs can be assessed according to the accumulation of acetylated α -tubulin and acetylated histones, respectively, using Western blot analysis. We initially examined the histone/ α -tubulin acetylation selectivity of **2**, **9**, and **10** (Figure 1). As reported previously,^{11b} **2** caused the accumulation of both acetylated histone H4 and acetylated α -tubulin. Like other non-

* To whom correspondence should be addressed. Tel and fax: +81–52–836–3407; e-mail: suzuki@phar.nagoya-cu.ac.jp; miyata-n@phar.nagoya-cu.ac.jp.

[†] Graduate School of Pharmaceutical Sciences, Nagoya City University.

[‡] RIKEN.

[§] CREST Research Project.

^a Abbreviations: HDAC, histone deacetylase; SIRT, sirtuin; AU, arbitrary unit.




Figure 1. Western blot detection of acetylated α -tubulin and histone H4 levels in HCT116 cells after incubation with compounds **2**, **9**, and **10** for 8 h.




Figure 2. Design of HDAC6-selective inhibitors.





Figure 3. Structures of the thioesters **12b–20b**.

hydroxamate HDAC inhibitors, compound **9** selectively caused histone H4 hyperacetylation, which indicates that compound **7** selectively inhibits nuclear HDACs over cytoplasmic HDAC6. However, unlike other non-hydroxamates, compound **10** increased the acetylation state of both histone H4 and α -tubulin. These results suggested that HDAC6-selective inhibitors might be obtained by structural modification of thiolate HDAC inhibitors.

In designing novel HDAC6-selective inhibitors, we focused initially on a small-molecular HDAC6-selective substrate **11**¹⁵ (Figure 2). Jung and co-workers found that compound **11** is selectively deacetylated by HDAC6 in preference to HDAC1 and HDAC3. This indicated that the structure of *N*-Boc and trifluoromethyl coumarinyl amide of compound **11** is selectively recognized by HDAC6, and so we considered that compound **12a**, in which the acetamide of **11** is replaced by a thiol, might behave as an HDAC6-selective inhibitor (Figure 2).

Since we used a cellular assay as the first screening, compound **12b** (Figure 3), the *S*-isobutyryl prodrug of compound **12a**, and its derivatives **13b–20b** were initially prepared. The route used for synthesis of compounds **12b–20b** is shown in Scheme 1. (*S*)-2-Amino-7-bromoheptanoic acid **21**¹⁶ was treated with (Boc)₂O to give *N*-Boc compound **22**. The condensation of carboxylic acid **22** with an appropriate amine afforded amides **23**. Bromides **23** were treated with thioiso-

Scheme 1^a



^a Reagents: (a) (Boc)₂O, Et₃N, THF, H₂O, rt, 96%; (b) ArNH₂, POCl₃, pyridine, -15°C , 10–48%; (c) RNH₂, 2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate, 1-hydroxybenzotriazole hydrate, Et₃N, DMF, rt, 35–63%; (d) thioisobutyric acid, Et₃N, EtOH, rt, 19–58%.




Figure 4. Western blot detection of acetylated α -tubulin and histone H4 levels in HCT116 cells after 8 h treatment with **12b–20b**.

butyric acid under alkaline conditions to yield the desired thioesters **12b–20b**.

We initially evaluated compound **12b** for the accumulation of acetylated α -tubulin and histone H4 using Western blot analysis (Figure 4). Although compound **12b** produced an increase in the accumulation of acetylated α -tubulin as compared with **9** and **10** (Figure 1), the selectivity was insufficient. In an attempt to improve the selectivity of the histone/ α -tubulin acetylation, we decided to carry out the structural conversion of compound **12b**. The coumarin structure derived from a substrate for fluorescent enzyme assays was replaced with various aromatic (**13b–16b**) or aliphatic (**17b–20b**) moieties (Figure 3). Interestingly, although the aromatic compounds **13b–16b** did not show high selectivity, the aliphatic compounds **17b–20b** produced a dose-dependent increase of α -tubulin acetylation without a major increase in acetylated histone H4 (Figure 4). These results indicated that the aliphatic compounds **17b–20b** selectively inhibit HDAC6 in preference to other HDACs in cells. To quantify the selectivity of cyclopentyl **17b**, one of the most active α -tubulin acetylating agents in this series, acetylated α -tubulin and histone H4, were measured over a range of concentrations (Figure 5). The estimated EC₅₀ values of cyclopentyl **17b** for α -tubulin acetylation and histone H4 acetylation were 0.23 μM and >32 μM , respectively, and the selectivity index (histone acetylation EC₅₀/ α -tubulin acetylation EC₅₀) was >140 which exceeded those of **2** (SI = 2.0) and **6** (SI = 75)^{11b} (Figure 5 and Figure 1S of Supporting Information).

To confirm the HDAC6-selectivity of these aliphatic compounds, we performed *in vitro* enzyme assays. For the enzyme assays, we synthesized compounds **17a–19a**, the corresponding thiols of **17b–19b**. Compounds **17a–19a** were prepared by the





Figure 5. Quantification of acetylated α -tubulin and histone H4 levels in HCT116 cells treated for 8 h with **17b**. Compound **17b** was insoluble in 0.1% DMSO–McCoy5A culture medium at concentrations $> 300 \mu\text{M}$.

Scheme 2^a



^a Reagents: (a) KSAC, EtOH, rt, 75–93%; (b) NaOH, H₂O, EtOH, rt, 71–77%.

Table 1. In Vitro HDAC1-, HDAC4-, and HDAC6-Inhibitory Activities of **17a–19a**^a

compd	IC ₅₀ (nM)			selectivity	
	HDAC1	HDAC4	HDAC6	HDAC1/ HDAC6	HDAC4/ HDAC6
1	21	34	81	0.26	0.42
6	ND ^c	ND	ND	4 ^b	4 ^b
7a	1210	1030	29	42	36
8a	1270	1140	36	35	32
9a	900	840	23	39	37

^a Values are means of at least three experiments. ^b Data taken from the literature (ref 17). ^c ND = No data.

procedure outlined in Scheme 2. Bromides **23** were treated with potassium thioacetate to give compounds **24**, after which hydrolysis of the thioesters under alkaline conditions gave the desired thiols **17a–19a**.

The results of enzyme assays are shown in Table 1. The HDAC6-inhibitory activity of compounds **17a–19a** was greater than that of **1** (IC₅₀ of **1** 81 nM, **17a** 29 nM, **18a** 36 nM, **19a** 23 nM). Furthermore, while **1** inhibited HDAC1 and HDAC4 rather than HDAC6 (HDAC1 IC₅₀/HDAC6 IC₅₀ = 0.26; HDAC4 IC₅₀/HDAC6 IC₅₀ = 0.42), compounds **17a–19a** excellently inhibited HDAC6 in preference to HDAC1 and HDAC4 (HDAC1 IC₅₀/HDAC6 IC₅₀ = 35–42; HDAC4 IC₅₀/HDAC6 IC₅₀ = 32–37). The HDAC6 selectivity of compounds **17a–19a** is about 10 times higher than that of **6** which showed about only 4-fold selectivity for HDAC6 over HDAC1 and HDAC6 in enzyme assays.¹⁷ These enzyme assays revealed that compounds **17a–19a** are potent and selective inhibitors of HDAC6. The reason that there is essentially no difference in the activity and selectivity of compounds **17a–19a** is unclear, but it is assumable that HDAC6 has a hydrophobic pocket where

some sterically bulky alkyl groups can be placed and other HDAC isoforms do not have such a pocket.

In conclusion, we have identified novel HDAC6-selective inhibitors whose designs were based on the structure of the HDAC6-selective substrate **11**. As far as we could determine, they are the first inhibitors that show significant HDAC6-selective inhibition in both cellular and enzyme assays. We have also established that the presence of a bulky alkyl group in these compounds is important for HDAC6-selective inhibition. The structures of the newly discovered HDAC6-selective inhibitors **17–20** are simpler than that of **6** and appear to be suitable as lead structures for the further development of superior HDAC6-selective inhibitors. These findings provide a basis for constructing new tools for probing the biology of HDAC6 and for finding new candidate antitumor agents with potentially fewer side effects.

Acknowledgment. This research was partly supported by Grants-in Aid for Young Scientists (B) from the Ministry of Education, Science, Culture, Sports, Science, Technology, Japan, and grants from the Hori Information Science Promotion Foundation, the Japan Securities Scholarship Foundation, the Tokyo Biochemical Research Foundation, Takeda Science Foundation, the TERUMO Lifescience Foundation and the Program for the Promotion of Fundamental studies in Health Science of the National Institute of Biomedical Innovation (NIBIO), Japan. We thank the Screening Committee of New Anticancer Agents, supported by a Grant-in-Aid for Scientific Research on Priority Area “Cancer” from the Ministry of Education, Culture, Sports, Science and Technology of Japan for HDAC1 inhibition assay results.

Supporting Information Available: Experimental procedures including spectral data for compounds **12–20** and biological methods (PDF). This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) (a) Grozinger, C. M.; Schreiber, S. L. Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors. *Chem. Biol.* **2002**, *9*, 3–16. (b) Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? *EMBO J.* **2000**, *19*, 1176–1179. (c) Kouzarides, T. Histone acetylases and deacetylases in cell proliferation. *Curr Opin. Genet. Dev.* **1999**, *9*, 40–48. (d) Hassig, C. A.; Schreiber, S. L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. *Curr. Opin. Chem. Biol.* **1997**, *1*, 300–308.
- (2) (a) Biel, M.; Wascholowski, V.; Giannis, A. Epigenetics-an epicenter of gene regulation: histones and histone-modifying enzymes. *Angew. Chem., Int. Ed. Engl.* **2005**, *44*, 3186–3216. (b) Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone deacetylation in epigenetics: an attractive target for anti-cancer therapy. *Med. Res. Rev.* **2005**, *25*, 261–309. (c) Suzuki, T.; Miyata, N. Epigenetic control using natural products and synthetic molecules. *Curr. Med. Chem.* **2006**, *13*, 935–958. (d) Schaefer, S.; Jung, M. Chromatin modifications as targets for new anticancer drugs. *Arch. Pharm.* **2005**, *338*, 347–357.
- (3) (a) Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumaraswamy, S.; Boyapalle, S.; Atadja, P.; Seto, E.; Bhalla, K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. *J. Biol. Chem.* **2005**, *280*, 26729–26734. (b) Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.; Yao, T. HDAC6 is a microtubule-associated deacetylase. *Nature* **2002**, *417*, 455–458. (c) Matsuyama, A.; Yoshimatsu, Y.; Shimazu, T.; Sumida, Y.; Osada, H.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Horinouchi, S.; Yoshida, M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. *EMBO J.* **2002**, *21*, 6820–6831. (d) Kovacs, J. J.; Murphy, P. J.; Gaillard, S.; Zhao, X.; Wu, J. T.; Nicchitta, C. V.; Yoshida, M.; Toft, D. O.; Pratt, W. B.; Yao, T. P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. *Mol. Cell* **2005**, *18*, 601–607.

- (4) Hideshima, T.; Bradner, J. E.; Wong, J.; Chauhan, D.; Richardson, P.; Schreiber, S. L.; Anderson, K. C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 8567–8572.
- (5) (a) Miller, T. A.; Witter, D. J.; Belvedere, S. Histone Deacetylase Inhibitors. *J. Med. Chem.* **2003**, *46*, 5097–5116. (b) Yoshida, M.; Matsuyama, A.; Komatsu, Y.; Nishino, N. From discovery to the coming generation of histone deacetylase inhibitors. *Curr. Med. Chem.* **2003**, *10*, 2351–2358. (c) Miller, T. A. Patent status of histone deacetylase inhibitors. *Expert Opin. Ther. Pat.* **2004**, *14*, 791–804. (d) Weinmann, H.; Ottow, E. Histone deacetylase inhibitors: a survey of recent patents. *Expert Opin. Ther. Pat.* **2005**, *15*, 1677–1690.
- (6) (a) Yoshida, M.; Kijima, M.; Akita, T.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. *J. Biol. Chem.* **1990**, *265*, 17174–17179. (b) Yoshida, M.; Horinouchi, S.; Beppu, T. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function. *BioEssays* **1995**, *17*, 423–430.
- (7) (a) Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 3003–3007. (b) Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 5705–5708.
- (8) Komatsu, Y.; Tomizaki, K. Y.; Tsukamoto, M.; Kato, T.; Nishino, N.; Sato, S.; Yamori, T.; Tsuruo, T.; Furumai, R.; Yoshida, M.; Horinouchi, S.; Hayashi, H. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. *Cancer Res.* **2001**, *61*, 4459–4466.
- (9) Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. *J. Biol. Chem.* **1993**, *268*, 22429–22435.
- (10) Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.; Yamashita, T.; Nakanishi, O. Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives. *J. Med. Chem.* **1999**, *42*, 3001–3003.
- (11) (a) Suzuki, T.; Miyata, N. Non-hydroxamate histone deacetylase inhibitors. *Curr. Med. Chem.* **2005**, *12*, 2867–2880. (b) Wong, J. C.; Hong, R.; Schreiber, S. L. Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity. *J. Am. Chem. Soc.* **2003**, *125*, 5586–5587. (c) Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 87–92. (d) Glaser, K. B.; Li, J.; Pease, L. J.; Staver, M. J.; Marcotte, P. A.; Guo, J.; Frey, R. R.; Garland, R. B.; Heyman, H. R.; Wada, C. K.; Vasudevan, A.; Michaelides, M. R.; Davidsen, S. K.; Curtin, M. L. Differential protein acetylation induced by novel histone deacetylase inhibitors. *Biochem. Biophys. Res. Commun.* **2004**, *325*, 683–690. (e) Suzuki, T.; Matsuura, A.; Kouketsu, A.; Hisakawa, S.; Nakagawa, H.; Miyata, N. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. *Bioorg. Med. Chem.* **2005**, *13*, 4332–4342.
- (12) (a) Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Butcher, R. A.; Schreiber, S. L. Multidimensional Chemical Genetic Analysis of Diversity-Oriented Synthesis-Derived Deacetylase Inhibitors Using Cell-Based Assays. *Chem. Biol.* **2003**, *10*, 383–396. (b) Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 4389–4394. (c) Sternson, S. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin. *Org. Lett.* **2001**, *3*, 4239–4242.
- (13) Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3313–3317.
- (14) Suzuki, T.; Nagano, Y.; Kouketsu, A.; Matsuura, A.; Maruyama, S.; Kurotaki, M.; Nakagawa, H.; Miyata, N. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. *J. Med. Chem.* **2005**, *48*, 1019–1032.
- (15) Heltweg, B.; Dequiedt, F.; Marshall, B. L.; Brauch, C.; Yoshida, M.; Nishino, N.; Verdin, E.; Jung, M. Subtype Selective Substrates for Histone Deacetylases. *J. Med. Chem.* **2004**, *47*, 5235–5243.
- (16) Watanabe, L. A.; Jose, B.; Kato, T.; Nishino, N.; Yoshida, M. Synthesis of l- α -amino- ω -bromoalkanoic acid for side chain modification. *Tetrahedron Lett.* **2004**, *45*, 491–494.
- (17) Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G. Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrollyl Hydroxyamides. *J. Med. Chem.* **2005**, *48*, 3344–3353.

JM060554Y